Merck & Co Inc is developing the cannabinoid receptor type 1 inverse agonist taranabant for the potential treatment of obesity and nicotine dependence. By October 2006, the drug had entered phase III trials for obesity, and by May 2008, a phase II study of taranabant as an aid to smoking cessation in chronic cigarette smokers had been completed.
|Original language||English (US)|
|Number of pages||14|
|Journal||Current Opinion in Investigational Drugs|
|State||Published - 2008|
ASJC Scopus subject areas
- Drug Discovery